Investor Relations

Corporate Profile

PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Stock Information

Exchange
Volume
Today's Open
Previous Close

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
10 November, 2022
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million , Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022 Total Operating Expenses Significantly Lower
Learn More
26 October, 2022
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
SPARTA, N.J. , Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
Learn More
12 September, 2022
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief SPARTA, N.J. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its
Learn More
Upcoming Events
More events are coming soon.